Search Thought Leadership

To refine your search select a single option or a combination of options:



Three green leaves
September 18, 2020
Sustainable Finance and Climate Change Risk in Financial Services: For Insurers
An update on the key global, European, and UK regulatory developments applicable to the insurance sector.
Displaying Thought Leadership item(s) associated with lawyer Carolyne Hathaway
1/2/3Next 46 results
  • March 2, 2012
    Partners John Manthei and Carolyne Hathaway analyze FDA's newest regulation of therapeutic biologic products in Bloomberg BNA's Pharmaceutical Law & Industry Report.
  • October 19, 2011
    In an article in Mass Device, Carolyne Hathaway, John Manthei and others discuss the key features of the FDA's latest 510(k) guidance.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.